European Mobtechs Dominate the Supply Market for Mobility-as-a-Service
7.3.2019 20:12:00 EET | Business Wire | Press release
A new study by PTOLEMUS Consulting Group finds that 12 of the top 17 B2B mobility platform providers in the world have their headquarters in Europe. These software suppliers have diverse backgrounds in road operation or technology but are all helped by a favourable environment and numerous city initiatives in Europe.
Frederic Bruneteau, PTOLEMUS’ Managing Director, stated: “While India just launched a vertically integrated national MaaS scheme, mobtechs are proposing a different model that relies on open software platforms for everybody to use. They are giving mobility operators an alternative to the inevitable dogfights between those who will eat (integrate) and those who will be eaten (integrated). This report sheds light on the specialist players that compete alongside government initiatives and giants such as Google and Uber”.
The Mobility Platform Suppliers handbook is the first to identify and appraise MaaS software suppliers and to clarify a very complex market. It will help cities, Public Transport Operators and mobility service providers choose the optimal model and deliver seamless mobility experiences.
The report maps the MaaS value chain and stakeholders. It also establishes the 6 levels of integration needed to deliver a complete MaaS solution. It includes an assessment of 17 key mobility platform suppliers, detailing their key clients, services, investors and case studies.
The handbook unpacks the MaaS ecosystem, stakeholders and architecture, covering:
- The necessary building blocks for a complete mobility platform
- The levels of MaaS integration
- The main players in each part of the MaaS value chain
- The top mobility platform providers
The study features:
- 150 pages of analysis of the complex ecosystem powering mobility-as-a-service,
- 17 MaaS platform suppliers assessed
- High level architecture of shared mobility platforms
- An independent ranking of the top technology providers in the MaaS market.
Download the abstract of the study here.
To discuss these questions directly with the authors, contact us at mobtech@ptolemus.com.
Suppliers analysed:
9 Transport Platform Providers:
- Bestmile
- INVERS
- Ecomobix
- Launch Mobility
- Omoove (Octo Telematics)
- Padam
- Ridecell
- Shotl
- Vulog
8 Mobility Platform Providers:
- A-to-Be (Brisa)
- Cubic
- Fluidtime (Kapsch)
- Moovel / Reach Now (BMW and Daimler)
- Moovit
- Optimile
- Siemens
- SkedGo
About PTOLEMUS Consulting Group
PTOLEMUS is the first strategy consulting & research firm entirely focused on connected & autonomous mobility. It assists leading public organisations, technology players, automotive OEMs, insurers and mobility service providers in defining & deploying their mobility strategies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190307005576/en/
Contact information
Annie Reddaway, +447912571379, areddaway@ptolemus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
